All News
Problems at the FDA
"While the Food and Drug Administration decision on new drugs usually follows the recommendations of the advisory committee..."; this oft used proviso is used to either indicate a pending FDA decision or an FDA decision that is contrary to the recommendation of the advisory committee co
Read ArticleRheumNow Podcast - Best of EULAR 2021
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Read ArticleNovel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis
Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).
Read ArticleLinks:
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com
Listen by Clicking below:
Read ArticleRheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
Read Article
Foot Pain Commonly Overlooked in RA
Foot pain is a common but underappreciated symptom of rheumatoid arthritis (RA) and can be associated with worse disease, European researchers found.
Read ArticleBest Interventions for Gout Flares
A recent metanalysis assessed the comparative efficacy of current first-line pharmacologic antiinflammatory interventions for gout flares and surmised that canakinumab and intravenous or intramuscular corticosteroids are superior to nonsteroidal antiinflammatory drugs [NSAIDs].
Read ArticleRheumNow Podcast – Heart, Lung & Liver (5.28.2021)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read ArticleMethotrexate Impairs COVID Vax Response
One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.
Read ArticleTriple DMARD Therapy Bested by Biologics in Swedish Registry
The Swedish Register compared outcomes of 1502 rheumatoid arthritis (RA) patients initiating either biologics plus methotrexate (MTX) or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) and showed similar rates of sustained remission.
Read ArticleCV Risk Decreased with Certain DMARDs in Rheumatoid Arthritis
A large prospective cohort study examined the comparative risks of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) and found that, methotrexate (MTX), abatacept (ABA) and TNF inhibitor (TNFi) use were associated with a decreased risk of CV events.
Read ArticleTocilizumab Augmented Efficacy in COVID-19 Pneumonia with High CRP
JAMA Internal Medicine report an analysis of recent and composite trial data suggesting that tocilizumab (TCZ) therapy in COVID-19–associated pneumonia patients with high CRP levels is likely to be effective.
Read ArticleCongress Slams AbbVie Over Price Hikes, 'Frivolous' Patents
House lawmakers on both sides of the aisle pummeled AbbVie CEO Richard Gonzalez for raising the price of two widely used drugs and for the company's "legally questionable" tactics to head off competition from biosimilars, despite pulling in healthy profits.
Read ArticleFactors Associated with COVID-19 Deaths in Rheumatic Patients
Analysis of data from the COVID-19 Global Rheumatology Alliance shows that rheumatic diseases infected with COVID-19 had a greater risk of death with age, comorbidities, high disease activity and few specific therapies.
Read ArticleRheumNow Podcast – Myth Busters (5.21.2021)
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com
Read ArticleLower Rates of Serious Infection with Ustekinumab in Psoriatic Disease
Patients with psoriasis or psoriatic arthritis who were being treated with ustekinumab (Stelara) had lower rates of serious hospitalized infections than patients receiving other biologics or small molecule therapies, a study utilizing data from two commercial claims databases found.
Read ArticleTocilizumab Risk of Diverticulitis and GI Perforation
A French registry analysis compared the risk of diverticulitis and gastrointestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with biologics and found a greater risk of both in patients receiving tocilizumab (TCZ) compared with those on rituximab (RTX) or abatacept (ABA
Read ArticleTotal Ankle Arthroplasty vs. Arthodeisis?
The Journal of Bone & Joint Surgery reports the findings of a 4-year trial comparing outcomes of total ankle arthroplasty (TAA) versus ankle arthrodesis (AA) in patients with severe ankle arthritis; finding that while both groups improved, TAA was associated with less pain and better function after 4 years.
Read ArticleCheckpoint Inhibitor Safety in Melanoma Patients with Autoimmune Disease
Immune checkpoint inhibitors (ICI) are well known to cause immune-related adverse events (irAEs). A study from the Dutch Melanoma Treatment Registry shows that the use of checkpoint inhibitors for advanced melanoma in AID (autoimmune disease) patients did not increase the risk of irAEs, except for those with preexisting IBD.
Read Article